Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TMDX Stock Forecast 2025-2026
$136.20
Current Price
$4.61B
Market Cap
Buy 6
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to TMDX Price Targets
+10.1%
To High Target of $150.00
+2.8%
To Median Target of $140.00
-24.4%
To Low Target of $103.00
TMDX Price Momentum
-4.8%
1 Week Change
+11.5%
1 Month Change
-6.7%
1 Year Change
+118.4%
Year-to-Date Change
-23.2%
From 52W High of $177.37
+147.6%
From 52W Low of $55.00
📊 TOP ANALYST CALLS
Did TMDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if TransMedics is one of their latest high-conviction picks.
Latest TMDX Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, TMDX has a bullish consensus with a median price target of $140.00 (ranging from $103.00 to $150.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $136.20, the median forecast implies a 2.8% upside. This outlook is supported by 6 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Suraj Kalia at Oppenheimer, projecting a 10.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TMDX Analyst Ratings
6
Buy
3
Hold
0
Sell
TMDX Price Target Range
Low
$103.00
Average
$140.00
High
$150.00
Current: $136.20
Latest TMDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TMDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 17, 2025 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $150.00 |
| Jun 17, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Jun 4, 2025 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $145.00 |
| Jun 3, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| May 9, 2025 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $125.00 |
| May 9, 2025 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $130.00 |
| Apr 29, 2025 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $105.00 |
| Apr 23, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Mar 26, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Mar 11, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $104.00 |
| Feb 5, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Dec 17, 2024 | JP Morgan | Allen Gong | Neutral | Downgrade | $75.00 |
| Dec 11, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Dec 11, 2024 | Baird | Joe Vruwink | Outperform | Maintains | $120.00 |
| Dec 11, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $90.00 |
| Dec 3, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $125.00 |
| Dec 3, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Nov 22, 2024 | Needham | Mike Matson | Hold | Downgrade | $109.00 |
| Nov 20, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $104.00 |
| Nov 20, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $110.00 |
TransMedics Group Inc. (TMDX) Competitors
The following stocks are similar to TransMedics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TMDX
TransMedics
mkt cap
4.83B
TransMedics Group Inc. (TMDX) Financial Data
TransMedics Group Inc. has a market capitalization of $4.61B with a P/E ratio of 95.9x. The company generates $488.23M in trailing twelve-month revenue with a 10.0% profit margin.
Revenue growth is +48.2% quarter-over-quarter, while maintaining an operating margin of +19.1% and return on equity of +23.0%.
Valuation Metrics
Market Cap
$4.61B
Enterprise Value
$4.82B
P/E Ratio
95.9x
PEG Ratio
82.5x
Price/Sales
9.4x
Growth & Margins
Revenue Growth (YoY)
+48.2%
Gross Margin
+61.5%
Operating Margin
+19.1%
Net Margin
+10.0%
EPS Growth
+110.6%
Financial Health
Cash/Price Ratio
+6.7%
Current Ratio
9.1x
Debt/Equity
194.7x
ROE
+23.0%
ROA
+4.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
TransMedics Group Inc. (TMDX) Business Model
About TransMedics Group Inc.
What They Do
Develops organ transplant therapy systems.
Business Model
The company commercializes its Organ Care System (OCS), a technology that preserves donor organs by replicating human body conditions. TransMedics generates revenue by selling its systems to hospitals and transplant centers, addressing the global demand for effective organ preservation.
Additional Information
Headquartered in Andover, Massachusetts, TransMedics enhances transplant outcomes by increasing the organ pool and reducing patient wait times. As a leader in healthcare technology, it aims to improve patient quality of life through innovative solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
728
CEO
Dr. Waleed H. Hassanein M.D.
Country
United States
IPO Year
2019
Website
www.transmedics.comTransMedics Group Inc. (TMDX) Latest News & Analysis
Latest News
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in TransMedics Group, Inc. (NASDAQ:TMDX) who purchased securities before February 3, 2022.
Why It Matters
The investigation into TransMedics may indicate potential legal issues or financial discrepancies, which could affect the stock's performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in TransMedics Group, Inc. (NASDAQ:TMDX) who purchased shares before February 3, 2022.
Why It Matters
The investigation into TransMedics may indicate potential legal issues or financial misconduct, which can impact stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
In May, three mid-cap stocks (market cap $2B-$10B) reported significant earnings beats, highlighted by substantial sales growth.
Why It Matters
Massive sales beats in mid-cap stocks suggest strong growth potential, indicating robust business performance that could attract investor interest and influence stock prices.
Source: MarketBeat
Market Sentiment:
Positive
These 24 Stocks Are Ripe for a Short Squeeze
6 days ago
Quick Summary
Recent negative sentiment in the stock market has led to significant short squeezes, resulting in large returns for investors.
Why It Matters
Negative sentiment can indicate oversold stocks, leading to short squeezes that may boost prices sharply, presenting potential high-return opportunities for investors.
Source: Schaeffers Research
Market Sentiment:
Neutral
Quick Summary
Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of shareholders.
Why It Matters
The investigation into TransMedics' leadership for potential fiduciary breaches could indicate financial mismanagement, impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of TransMedics Group (NASDAQ:TMDX) who purchased shares before February 3, 2022.
Why It Matters
The investigation suggests potential legal issues for TransMedics, which could impact stock performance, investor sentiment, and future financial stability.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About TMDX Stock
What is TransMedics Group Inc.'s (TMDX) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, TransMedics Group Inc. (TMDX) has a median price target of $140.00. The highest price target is $150.00 and the lowest is $103.00.
Is TMDX stock a good investment in 2025?
According to current analyst ratings, TMDX has 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $136.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TMDX stock?
Wall Street analysts predict TMDX stock could reach $140.00 in the next 12 months. This represents a 2.8% increase from the current price of $136.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is TransMedics Group Inc.'s business model?
The company commercializes its Organ Care System (OCS), a technology that preserves donor organs by replicating human body conditions. TransMedics generates revenue by selling its systems to hospitals and transplant centers, addressing the global demand for effective organ preservation.
What is the highest forecasted price for TMDX TransMedics Group Inc.?
The highest price target for TMDX is $150.00 from Suraj Kalia at Oppenheimer, which represents a 10.1% increase from the current price of $136.20.
What is the lowest forecasted price for TMDX TransMedics Group Inc.?
The lowest price target for TMDX is $103.00 from at , which represents a -24.4% decrease from the current price of $136.20.
What is the overall TMDX consensus from analysts for TransMedics Group Inc.?
The overall analyst consensus for TMDX is bullish. Out of 14 Wall Street analysts, 6 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $140.00.
How accurate are TMDX stock price projections?
Stock price projections, including those for TransMedics Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 5:28 PM UTC